Antigen Test Positivity After COVID-19 Isolation - Yukon-Kuskokwim Delta Region, Alaska, January-February 2022
- PMID: 35202352
- DOI: 10.15585/mmwr.mm7108a3
Antigen Test Positivity After COVID-19 Isolation - Yukon-Kuskokwim Delta Region, Alaska, January-February 2022
Abstract
Isolation is recommended during acute infection with SARS-CoV-2, the virus that causes COVID-19, but the duration of infectiousness varies among individual persons. Rapid antigen test results have been correlated with detection of viable virus (1-3) and might inform isolation guidance, but data are limited for the recently emerged SARS-CoV-2 B.1.1.529 (Omicron) variant. On January 5, 2022, the Yukon-Kuskokwim Health Corporation (YKHC) recommended that persons with SARS-CoV-2 infection isolate for 10 days after symptom onset (or, for asymptomatic persons, 10 days after a positive nucleic acid amplification or antigen test result). However, isolation could end after 5-9 days if symptoms were resolving or absent, fever was absent for ≥24 hours without fever-reducing medications, and an Abbott BinaxNOW COVID-19 Ag (BinaxNOW) rapid antigen test result was negative. Antigen test results and associated individual characteristics were analyzed among 3,502 infections reported to YKHC during January 1-February 9, 2022. After 5-9 days, 396 of 729 persons evaluated (54.3%) had a positive antigen test result, with a declining percentage positive over time. In a multivariable model, a positive antigen test result was more likely after 5 days compared with 9 days (adjusted odds ratio [aOR] = 6.39) or after symptomatic infection (aOR = 9.63), and less likely after previous infection (aOR = 0.30), receipt of a primary COVID-19 vaccination series (aOR = 0.60), or after both previous infection and receipt of a primary COVID-19 vaccination series (aOR = 0.17). Antigen tests might be a useful tool to guide recommendations for isolation after SARS-CoV-2 infection. During the 10 days after infection, persons might be infectious to others and are recommended to wear a well-fitting mask when around others, even if ending isolation after 5 days.
Conflict of interest statement
All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.
Similar articles
-
COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods.JAMA Netw Open. 2022 Oct 3;5(10):e2235844. doi: 10.1001/jamanetworkopen.2022.35844. JAMA Netw Open. 2022. PMID: 36215069 Free PMC article.
-
Use of Rapid Antigen Testing for SARS-CoV-2 in Remote Communities - Yukon-Kuskokwim Delta Region, Alaska, September 15, 2020-March 1, 2021.MMWR Morb Mortal Wkly Rep. 2021 Aug 20;70(33):1120-1123. doi: 10.15585/mmwr.mm7033a3. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34411078 Free PMC article.
-
Evaluation of Abbott BinaxNOW Rapid Antigen Test for SARS-CoV-2 Infection at Two Community-Based Testing Sites - Pima County, Arizona, November 3-17, 2020.MMWR Morb Mortal Wkly Rep. 2021 Jan 22;70(3):100-105. doi: 10.15585/mmwr.mm7003e3. MMWR Morb Mortal Wkly Rep. 2021. PMID: 33476316 Free PMC article.
-
Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection.Cochrane Database Syst Rev. 2022 Jul 22;7(7):CD013705. doi: 10.1002/14651858.CD013705.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866452 Free PMC article. Review.
-
Demand for longer quarantine period among common and uncommon COVID-19 infections: a scoping review.Infect Dis Poverty. 2021 Apr 26;10(1):56. doi: 10.1186/s40249-021-00847-y. Infect Dis Poverty. 2021. PMID: 33902695 Free PMC article. Review.
Cited by
-
When Should Healthcare Workers With Coronavirus Disease 2019 (COVID-19) Return to Work? An Analysis of Follow-up Antigen Test Results After a Positive COVID Test.Open Forum Infect Dis. 2023 Mar 3;10(3):ofad114. doi: 10.1093/ofid/ofad114. eCollection 2023 Mar. Open Forum Infect Dis. 2023. PMID: 36968971 Free PMC article.
-
Too Many Deaths, Too Many Left Behind: A People's External Review of the U.S. Centers for Disease Control and Prevention's COVID-19 Pandemic Response.AJPM Focus. 2024 Feb 25;3(4):100207. doi: 10.1016/j.focus.2024.100207. eCollection 2024 Aug. AJPM Focus. 2024. PMID: 38770235 Free PMC article.
-
COVID-19 testing protocols to guide duration of isolation: a cost-effectiveness analysis.BMC Public Health. 2023 May 11;23(1):864. doi: 10.1186/s12889-023-15762-0. BMC Public Health. 2023. PMID: 37170225 Free PMC article.
-
COVID-19 Symptoms and Duration of Rapid Antigen Test Positivity at a Community Testing and Surveillance Site During Pre-Delta, Delta, and Omicron BA.1 Periods.JAMA Netw Open. 2022 Oct 3;5(10):e2235844. doi: 10.1001/jamanetworkopen.2022.35844. JAMA Netw Open. 2022. PMID: 36215069 Free PMC article.
-
The effect of ivermectin on the viral load and culture viability in early treatment of nonhospitalized patients with mild COVID-19 - a double-blind, randomized placebo-controlled trial.Int J Infect Dis. 2022 Sep;122:733-740. doi: 10.1016/j.ijid.2022.07.003. Epub 2022 Jul 8. Int J Infect Dis. 2022. PMID: 35811080 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
